SceneRay

SceneRay is an innovative high-tech medical device company headquartered in the Suzhou Industrial Park, China, dedicated to the research, development, production, and sales of deep brain stimulation (DBS) systems and brain-computer interface technology. Founded in 2011, the company focuses on Class III implantable active medical devices, specializing in DBS systems for Parkinson's disease and brain-computer interfaces for treating addictive mental illnesses such as opioid use disorder. SceneRay's proprietary Neurestora system received approval from China's National Medical Products Administration in December 2025 as the world's first DBS-based solution for treating moderate-to-severe opioid addiction. The company has also received FDA Breakthrough Device Designation for its dual-target DBS therapy and has conducted over 14 years of clinical research. Its team includes more than 200 experts and graduates from leading Chinese universities including Tsinghua and Peking University.